Company: SXTPW
Filing Date: 2025-01-30
Form Type: 424B5
Source: 0001213900-25-008098
Chunk: 9

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-30
Form: 424B5
Chunk 9
---
 | Treatment of Acute Babesiosis.                                                                                                                  
 There are up to 38,000 cases of potentially treatable acute symptomatic babesiosis (red blood cell infections caused by deer tick               
 bites) in the United States each year.10 Approximately 650 of these cases are hospitalizations, a smaller fraction of                           
 which represents immunosuppressed individuals.11 Symptomatic babesiosis is usually treated with a minimum ten day course                        
 of atovaquone and azithromycin which is extended to six weeks in the immunosuppressed, who may also experience relapses requiring               
 multiple hospitalizations.12 This is much longer than equivalent serious parasitic diseases such as malaria where the                           
 goal is a three-day regimen. In a recently published case series Tafenoquine in combination with standard of care cured 80% of immunosuppressed 
 patients with relapsing babesiosis and the investigators stated in a press release that “Tafenoquine is                                         
 going to make a huge difference, I think, in people who are severely immunocompromised.” 13                                                     |

| ● | Prevention of Tick-Borne                                                                                                             
 Diseases. Post-exposure prophylaxis or early treatment with, respectively, a single dose or several week regimen of doxycycline      
 following a tick-bite is a recognized indication to prevent the complications of Lyme disease. There may be more than 400,000 such   
 tick bites in the United States requiring medical treatment each year. This estimate is based on the observation that approximately  
 50,000 tick bites are treated in U.S. hospital emergency rooms each year; however, this calculation represents only about 12% of     
 actual treated tick bites based on observations from comparable ex-U.S health systems.14 Unlike Lyme disease, there is               
 no characteristic rash associated with early infection and no reliable diagnostic tests. Thus, an individual bitten by a tick cannot 
 know whether they have also been infected with babesiosis. It is likely that a drug proven to be effective for this indication for   
 babesiosis would also be used in conjunction with Lyme prophylaxis.                                                                  |

Treatment and Prevention of Fungal Infections We are evaluating Tafenoquine for potential utility in the following fungal diseases:

| ● | Treatment of Candida                                                                                                         
 infections. According to the CDC, there are 50,000 reported cases of candidiasis (a type of fungal infection) each year in   
 the United States and up to 1,900 clinical cases of C. auris,